Sugi Predict

Sugi Predict / Compounds / SCHEMBL1844682

SCHEMBL1844682

SCHEMBL1844682

COCCOc1ccc(CO)cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 2/20 0.45
▸ NAMPT P43490 1/20 0.44
▸ PIK3CD O00329 2/20 0.44
▸ PIK3CA P42336 2/20 0.44
▸ PIK3CB P42338 2/20 0.44
▸ PIK3CG P48736 2/20 0.44
▸ PI4KA P42356 1/20 0.44
▸ PI4KB Q9UBF8 1/20 0.44
▸ LIPG Q9Y5X9 1/20 0.43
▸ CBFB Q13951 1/20 0.40
▸ CD274 Q9NZQ7 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ LTA4H P09960 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ PTGES O14684 1/20 0.35
▸ MTOR P42345 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944149 0.88 KDM4E (0.43) ACACBNAMPTPIK3CDPIK3CAPIK3CB
SCHEMBL5247460 0.87 MAPT (0.56) ACACBNAMPTLIPGNPC1RAB9A
SCHEMBL13185115 0.84 PIK3CD (0.45) ACACBNAMPTPIK3CDPIK3CAPIK3CB
SCHEMBL9446671 0.83 MAPT (0.39) ACACBHRH3LTA4HPTGES
SCHEMBL1846864 0.82 PIK3CD (0.44) ACACBNAMPTPIK3CDPIK3CAPIK3CB
SCHEMBL16233092 0.82 PIK3CD (0.47) ACACBNAMPTPIK3CDPIK3CAPIK3CB
SCHEMBL29491632 0.81 NNMT (0.47) PIK3CDPIK3CAPIK3CBPIK3CGNPC1
SCHEMBL247713 0.81 NNMT (0.47) PIK3CDPIK3CAPIK3CBPIK3CGNPC1
SCHEMBL31434245 0.80 CHEK2 (0.36) ACACBNAMPTPIK3CDPIK3CAPIK3CB
SCHEMBL20550551 0.80 CHEK2 (0.36) ACACBNAMPTPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1318140-B9 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-05-21 — — EP disclosed
US-20140038978-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS ASTRAZENECA AB (SE) 2014-02-06 — — US disclosed
US-20140038978-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS ASTRAZENECA AB (SE) 2014-02-06 — — US disclosed
CN-101128427-B Heterocyclic compounds as ccr2b antagonists ASTRAZENECA AB 2013-03-27 — — CN disclosed
CN-1474803-B Amide derivatives and their use for the preparation of medicaments MITSUBISHI TANABE PHARMA CORP 2012-11-21 — — CN disclosed
US-20120264762-A1 Heterocyclic Compounds as CCR2 Antagonists ASTRAZENECA AB (SE) 2012-10-18 — — US disclosed
US-20120264762-A1 Heterocyclic Compounds as CCR2 Antagonists ASTRAZENECA AB (SE) 2012-10-18 — — US disclosed
US-8198454-B2 Amide derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-12 — — US disclosed
US-20110136820-A1 Heterocyclic Compounds as CCR2 Antagonists ASTRAZENECA AB (SE) 2011-06-09 — — US disclosed
US-20110136820-A1 Heterocyclic Compounds as CCR2 Antagonists ASTRAZENECA AB (SE) 2011-06-09 — — US disclosed
US-20100041656-A1 Novel amide derivatives and medicinal use thereof NAKAMURA MITSUBARU 2010-02-18 — — US disclosed
US-20090099156-A1 Heterocyclic Compounds as Ccr2b antagonists ASTRAZENECA AB (SE) 2009-04-16 — — US disclosed
US-20090099156-A1 Heterocyclic Compounds as Ccr2b antagonists ASTRAZENECA AB (SE) 2009-04-16 — — US disclosed
CN-101128427-A Heterocyclic compounds as ccr2b antagonists ASTRAZENECA AB (SE) 2008-02-20 — — CN disclosed
US-20040138223-A1 Novel amide derivatives and medicinal use thereof ugs MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-07-15 — — US disclosed
CN-1474803-A Novel amide derivative and medical use thereof ������ҩ��ʽ���� 2004-02-11 — — CN disclosed
EP-1318140-A1 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS Mitsubishi Pharma Corporation (JP) 2003-06-11 — — EP disclosed
US-5216170-A Promoters of livestock; treatment of obesity BAYER AKTIENGESELLSCHAFT (DE) 1993-06-01 — — US disclosed
US-5028617-A Heteroarylethanol-pyridylalkylamines for controlling animal growth BAYER AKTIENGESELLSCHAFT (DE) 1991-07-02 — — US disclosed
EP-0379928-A2 Aryl- and heteroarylethanol-pyridylalkylamines, process for their preparation and their use as performance stimulators by animals and as anti-adipositas agent BAYER AG (DE) 1990-08-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264762-A1 Heterocyclic Compounds as CCR2 Antagonists CCR2, CCR3, CXCR2 ACACB 3962/4885NAMPT 1329/4885PIK3CD 4833/4885
US-20110136820-A1 Heterocyclic Compounds as CCR2 Antagonists CCR2, CCR3, CXCR2 ACACB 3962/4885NAMPT 1329/4885PIK3CD 4833/4885
US-20140038978-A1 HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS CCR2, CCR3, CXCR2 ACACB 3345/4885NAMPT 1527/4885PIK3CD 4848/4885
US-20090099156-A1 Heterocyclic Compounds as Ccr2b antagonists CCR2, CCR3, CXCR2 ACACB 3268/4885NAMPT 1465/4885PIK3CD 4853/4885
US-20100041656-A1 Novel amide derivatives and medicinal use thereof C5AR1, C5AR2, C3AR1 ACACB 680/4885NAMPT 1160/4885PIK3CD 1654/4885
US-20040138223-A1 Novel amide derivatives and medicinal use thereof ugs C5AR1, C5AR2, C1S ACACB 1179/4885NAMPT 1459/4885PIK3CD 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.